Cargando…
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555974/ https://www.ncbi.nlm.nih.gov/pubmed/34756322 http://dx.doi.org/10.1016/j.reumae.2020.03.005 |
| _version_ | 1784592086603923456 |
|---|---|
| author | Sanchez-Pernaute, Olga Romero-Bueno, Fredeswinda I. Selva-O’Callaghan, Albert |
| author_facet | Sanchez-Pernaute, Olga Romero-Bueno, Fredeswinda I. Selva-O’Callaghan, Albert |
| author_sort | Sanchez-Pernaute, Olga |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8555974 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85559742021-11-01 Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() Sanchez-Pernaute, Olga Romero-Bueno, Fredeswinda I. Selva-O’Callaghan, Albert Reumatol Clin (Engl Ed) Letter to the Editor Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021-11 2021-10-29 /pmc/articles/PMC8555974/ /pubmed/34756322 http://dx.doi.org/10.1016/j.reumae.2020.03.005 Text en © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Sanchez-Pernaute, Olga Romero-Bueno, Fredeswinda I. Selva-O’Callaghan, Albert Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title_full | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title_fullStr | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title_full_unstemmed | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title_short | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia() |
| title_sort | why choose cyclosporin a as first-line therapy in covid-19 pneumonia() |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555974/ https://www.ncbi.nlm.nih.gov/pubmed/34756322 http://dx.doi.org/10.1016/j.reumae.2020.03.005 |
| work_keys_str_mv | AT sanchezpernauteolga whychoosecyclosporinaasfirstlinetherapyincovid19pneumonia AT romerobuenofredeswindai whychoosecyclosporinaasfirstlinetherapyincovid19pneumonia AT selvaocallaghanalbert whychoosecyclosporinaasfirstlinetherapyincovid19pneumonia |